Drugs for Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 186)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Fluorometholone |
Approved, Investigational |
Phase 4 |
|
426-13-1 |
9878 |
Synonyms:
(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one
(6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione
426-13-1
9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione
9-fluoro-11b,17-Dihydroxy-6a-methylpregna-1,4-diene-3,20-dione
9-fluoro-11beta,17-Dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
9-fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione
AC1L1U0Y
AC-3520
AI3-52813
Alcon brand OF fluorometholone
Alcon Brand of Fluorometholone
Allergan brand 1 OF fluorometholone
Allergan Brand 1 of Fluorometholone
Allergan brand 2 OF fluorometholone
Allergan Brand 2 of Fluorometholone
Allergan brand 3 OF fluorometholone
Allergan Brand 3 of Fluorometholone
BPBio1_001029
BRD-K64862097-001-03-9
BSPBio_000935
CHEMBL1200600
CID9878
component of Neo-Oxylone
Cortilet
Cortisdin
D005469
D01367
DB00324
Delmeson
Efflumidex
EINECS 207-041-5
F0414
F9381_SIGMA
Fluaton
Flucon
Flucon, isopto
Flucon, Isopto
Flumetholon
Fluor Op
Fluor OP
Fluormetholon
Fluormetholone
Fluormetholonum
fluoro Ophtal
Fluoro Ophtal
Fluoromethalone
Fluorometholon
fluorometholone
Fluorometholone
Fluorométholone
Fluorometholone (JP15/USP/INN)
Fluorometholone [INN:BAN:JAN]
Fluorometholonum
Fluorometholonum [INN-Latin]
Fluorometolona
Fluorometolona [INN-Spanish]
|
Fluorometolone
Fluorometolone [DCIT]
fluoro-Ophtal
Fluoro-Ophtal
Fluor-Op
Fluor-OP
Fluor-op (TN)
Fluoropos
FML
Fml (TN)
FML Forte
FML Liquifilm
FML S.O.P
FML-S Liquifilm
HMS1570O17
Isdin brand OF fluorometholone
Isdin Brand of Fluorometholone
isopto Flucon
Isopto Flucon
Loticort
LS-118455
MLS000069537
MLS001076157
MolPort-003-941-413
NCGC00021575-03
NCI60_002886
Neo-Oxylone
Novartis brand OF fluorometholone
Novartis Brand of Fluorometholone
NSC 33001
NSC33001
NSC-33001
Oxylone
Oxylone (TN)
Pharm allergan brand OF fluorometholone
Pharm Allergan Brand of Fluorometholone
Pharm-allergan brand OF fluorometholone
Pharm-Allergan Brand of Fluorometholone
Pharmascience brand OF fluorometholone
Pharmascience Brand of Fluorometholone
PMS Fluorometholone
PMS-Fluorometholone
Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl- (8CI)
Prestwick_227
Prestwick0_000718
Prestwick1_000718
Prestwick2_000718
Prestwick3_000718
SMR000058598
SPBio_002856
Trilcin
U 8614
UNII-SV0CSG527L
Ursapharm brand OF fluorometholone
Ursapharm Brand of Fluorometholone
Ursnon
Winzer brand OF fluorometholone
Winzer Brand of Fluorometholone
ZINC03876158
|
|
2 |
|
Loteprednol |
Approved, Experimental |
Phase 4 |
|
129260-79-3, 82034-46-6 |
9865442 444025 |
Synonyms:
17-Ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, chloromethyl
82034-46-6
AC1L9FKJ
AKOS005145741
Alrex
Alrex, Lotemax, Loteprednol etabonate
CDDD-5604
CEHOAC
CHEBI:31784
CHEMBL1200865
chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate
chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate
Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
CID444025
CPD000469178
D01689
DB00873
Etabonate, loteprednol
HGP-1
|
HMS2051F16
IDR-90102
IDR-90103
Locort
Loteflam
Lotemax
Lotemax (TN)
Loteprednol
Loteprednol etabonate
Loteprednol etabonate (JAN/USAN)
Loterox
MLS001424221
MolPort-003-848-424
NCGC00164594-01
P-5604
S1669_Selleck
SAM001246630
SMR000469178
ZINC03920673
|
|
3 |
|
Atropine |
Approved, Vet_approved |
Phase 4 |
|
51-55-8, 5908-99-6 |
174174 |
Synonyms:
(+-)-atropine
(+-)-Atropine
(+-)-hyoscyamine
(+-)-Hyoscyamine
(+,-)-Tropyl tropate
(+,-)-Tropyl tropic acid
(+/-)-Atropine
(+/-)-Hyoscyamine
(±)-atropine
(±)-hyoscyamine
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropic acid
(3-endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
(3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[3.2.1]octane
(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
[(1S,5R)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
[(1S,5R)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoic acid
120-29-6
1alphaH,5alphaH-Tropan-3alpha-ol
1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester)
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester)
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI)
1alphaH,5alphaH-Tropan-3beta-ol
2-Phenylhydracrylic acid 3-alpha-tropanyl ester
51-55-8
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoic acid
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropic acid
8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropionate
A0132_SIGMA
A2468_SIGMA
AC1L5AX3
AC1Q3XL2
ACon1_000046
AI3-60219
AKOS005137976
Ambap120-29-6
Anaspaz
Atropair
Atropen
Atropen (TN)
Atropin
Atropin [German]
Atropina
Atropina [Italian]
a-Tropine
Atropine
ATROPINE
Atropine (USP)
Atropine [BAN]
Atropine Care
Atropine sulfate
Atropine Sulfate S.O.P.
Atropin-flexiolen
atropinium cation
atropinium(1+)
Atropinol
Atropinum
Atropt
Atrosulf
b eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
Belladenal
Bellergal-S
Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]
beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]
bmse000649
BRD-A27290375-001-01-8
|
C01479
C17H23NO3
CAS-120-29-6
CCRIS 3080
CHEBI:15742
CHEBI:15884
CHEBI:16684
CHEBI:537621
CHEBI:57858
CHEMBL1235490
CID174174
CPD001906768
Cytospaz
D00113
d1-hyoscyamine
DB00572
DB04026
dl-Hyoscyamine
DL-Hyoscyamine
DL-Tropanyl 2-hydroxy-1-phenylpropionate
DL-Tropyl tropate
dl-tropyltropate
dl-Tropyltropate
DL-Tropyltropate
DL-Tropyltropic acid
EINECS 200-104-8
endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
endo-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
Eyesules
FT-0082634
HMS2089A16
HSDB 2199
hyoscyamine
Hyoscyamine sulfate
Isopto Atropine
Isopto-atropine
I-Tropine
LS-7203
MEGxp0_001878
Minims
Minims Atropine
MLS000069795
MLS001148094
MLS002695888
MolPort-001-742-593
MolPort-003-986-158
NCGC00016370-01
NCGC00142514-01
NCGC00142514-03
nchembio.307-comp21
Neo-Diophen
NP-010662
Ocu-Tropine
OR22908
Protamine & Atropine
SAM002554885
SMR000058248
ST057178
ST057655
T0534
TL8000018
tropan-3alpha-ol
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
tropan-3beta-ol
Tropanol
Tropic acid, 3-alpha-tropanyl ester
Tropic acid, ester with tropine
Tropine (+/-)-tropate
Tropine tropate
Tropine tropic acid
Tropine, tropate (ester)
Troyl tropate
Urised
|
|
4 |
|
Levofloxacin |
Approved, Investigational |
Phase 4 |
|
100986-85-4 |
149096 |
Synonyms:
(−
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-Ofloxacin
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(R)-isomer
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-Ofloxacin
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
)-Ofloxacin
100986-85-4
100986-86-5
28266_FLUKA
28266_SIGMA
AC1L3YF8
AC-7593
Aeroquin
Ambap100986-85-4
Anhydrous, levofloxacin
BRD-K09471561-001-06-7
BSPBio_002689
C07660
C18H20FN3O4
C18H20FN3O4.H2O
CCRIS 4073
CCRIS 4074
CHEMBL33
CID149096
CPD000466387
Cravit
Cravit (TN)
Cravit Ophthalmic
D08120
DB01137
d-Levofloxacin
DR 3354
DR3355
DR-3355
DR-3355: L-isomer of ofloxacin
Elequine
Floxacin
Floxel
Floxin
HMS1922J07
HMS2051G04
HMS2090O10
HMS2093E18
HR 355
HR-355
Iquix
KBio2_002199
|
KBio2_004767
KBio2_007335
KBio3_001909
KBioGR_001605
KBioSS_002199
L0193
Leroxacin
Lesacin
Levaquin
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Levofloxacin
LEVOFLOXACIN
Levofloxacin (INN)
Levofloxacin [USAN:INN:JAN]
Levofloxacin anhydrous
Levofloxacin hydrate
Levofloxacin tablet, suspension or intravenous
Levofloxacine
Levofloxacine [INN-French]
Levofloxacino
Levofloxacino [INN-Spanish]
Levofloxacinum
Levofloxacinum [INN-Latin]
Levokacin
Levox
Levoxacin
LFX
L-Ofloxacin
LS-133260
LS-171761
LVX
MLS000759524
MLS001165709
MLS001423977
MolPort-002-885-835
Mosardal
MP-376
NCGC00178529-01
Nofaxin
Ofloxacin
Ofloxacin S-(-)-form
Ofloxacin, (S)-isomer
Oftaquix
Quixin
Reskuin
R-Ofloxacin
RWJ 25213-097
RWJ-25213
S-(-)-Ofloxacin
S1940_Selleck
SAM001246758
SMR000466387
SPBio_001891
Spectrum_001719
SPECTRUM1504260
Spectrum2_001676
Spectrum3_000995
Spectrum4_001123
Spectrum5_001438
Tavanic
Volequin
|
|
5 |
|
Ofloxacin |
Approved |
Phase 4 |
|
82419-36-1 |
4583 |
Synonyms:
( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
(+/-)-Floxin
118120-51-7 (hydrochloride)
33703_FLUKA
33703_RIEDEL
82419-36-1
83380-47-6
85344-55-4
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
AB00513820
AC1L1IHM
AC-7616
Akilen
AKOS001033517
Baccidal
Bactocin
BB_SC-1252
BPBio1_000345
BRD-A24228527-001-05-9
BRN 3657947
BSPBio_000313
BSPBio_003117
C07321
C18H20FN3O4
CCRIS 5233
CHEBI:7731
CHEMBL4
CID4583
CPD000058192
D00453
Danoflox
DB01165
DEXTROFLOXACINE
DivK1c_000721
DL 8280
DL-8280
DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin
Effexin
EU-0100904
Exocin
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
Floxin (TN)
FLOXIN IN DEXTROSE 5%
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Floxin otic
Floxstat
Fugacin
HMS1568P15
HMS1921H12
HMS2090F07
HMS2092B10
HMS502E03
Hoe 280
HOE 280
Hoe-280
I06-0112
I06-0380
IDI1_000721
Inoflox
KBio1_000721
KBio2_001666
KBio2_004234
KBio2_006802
KBio3_002617
KBioGR_000667
KBioSS_001666
Kinflocin
Kinoxacin
Liflox
Lopac0_000904
Loxinter
LS-133259
Marfloxacin
Medofloxine
Mergexin
MLS000028749
MLS001074203
MolPort-000-422-241
MolPort-000-873-068
NCGC00015772-02
NCGC00015772-10
|
NCGC00094219-01
NCGC00094219-02
NCGC00094219-03
NCGC00094219-04
NCGC00094219-05
NCGC00094219-06
NCGC00178284-01
NCGC00178284-02
NINDS_000721
Novecin
NSC727071
Nufafloqo
O 8757
O8757_SIGMA
Obide
Occidal
Ocuflox
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
ofloxacin
Ofloxacin
Ofloxacin (JP15/USP/INN)
Ofloxacin [USAN:BAN:INN:JAN]
Ofloxacin hydrochloride
Ofloxacin Otic
Ofloxacin, (S)-Isomer
Ofloxacina
Ofloxacina [DCIT]
Ofloxacine
Ofloxacine [French]
Ofloxacino
Ofloxacino [Spanish]
Ofloxacinum
Ofloxacinum [Latin]
Ofloxin
OFLX
Ofus
OFX
Onexacin
Operan
Oprea1_242882
ORF 18489
ORF-28489
Orocin
Otonil
Oxaldin
Pharflox
Praxin
Prestwick0_000237
Prestwick1_000237
Prestwick2_000237
Prestwick3_000237
PT 01
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Ru-43280
S1463_Selleck
SAM002264629
Sinflo
SMR000058192
SPBio_001387
SPBio_002234
Spectrum_001186
SPECTRUM1502044
Spectrum2_001464
Spectrum3_001499
Spectrum4_000324
Spectrum5_001063
STK256723
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
UNII-A4P49JAZ9H
Uro Tarivid
Viotisone
Visiren
WP-0405
XED
Zanocin
|
|
6 |
|
Ketorolac |
Approved |
Phase 4 |
|
66635-83-4, 74103-06-3 |
3826 |
Synonyms:
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-isomer
(+-)-Ketorolac
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC1L1GSW
AC-545
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
I14-2832
Ketoralac
|
ketorolac
Ketorolac
Kétorolac
Ketorolac (INN)
Ketorolac [INN:BAN]
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
rac-Ketorolac
RS 37619
RS-37619
SBB067312
STL018674
Toradol
Toradol (TN)
UNII-YZI5105V0L
|
|
7 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-88-6, 585-86-4 |
493591 |
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
Lactitol
Lactitolum
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
8 |
|
Nepafenac |
Approved, Investigational |
Phase 4 |
|
78281-72-8 |
151075 |
Synonyms:
2-amino-3-benzoylbenzeneacetamide
2-amino-3-Benzoylbenzeneacetamide
AHR 9434
AHR-9434
AL 6515
AL-6515
|
Amfenac amide
Nepafenac
Népafénac
Nepafenaco
Nepafenacum
Nevanac
|
|
9 |
|
Atracurium |
Approved, Experimental, Investigational |
Phase 4 |
|
64228-79-1 |
47319 |
Synonyms:
1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
64228-79-1
64228-81-5 (besylate)
AB00514743
AC1L2HUF
AC1Q67HR
Atracurium
Atracurium besilate
Atracurium besylate
Atracurium dibesylate
Atracurium Dibesylate
Besilate, atracurium
BPBio1_000011
BRN 1523633
BSPBio_000009
BW 33a
BW33a
BW-33a
|
C07548
C53H70N2O12
CHEBI:2914
CHEMBL1360
CID47319
DB00732
glaxo Wellcome brand OF atracurium besilate
HMS2090I21
LS-86151
MolPort-005-932-641
Pisa brand OF atracurium besilate
Prestwick1_000005
Prestwick2_000005
Prestwick3_000005
Relatrac
SPBio_001930
Tracrium
UNII-2GQ1IRY63P
Wellcome brand OF atracurium besilate
|
|
10 |
|
Hydrogen peroxide |
Approved, Vet_approved |
Phase 4 |
|
7722-84-1 |
784 |
Synonyms:
[OH(OH)]
Adeka super el
Albone
Albone 35
Albone DS
Anti-keim 50
Asepticper
Baquashock
CIX
Clarigel gold
Crestal whitestrips
Crystacide
Dentasept
Deslime LP
Dihydrogen dioxide
H2O2
Hioxyl
Hipox
HOOH
Hybrite
Hydrogen dioxide
Hydrogen peroxide (H2O2)
Hydroperoxide
Inhibine
Lase peroxide
|
Lensan a
Magic bleaching
Metrokur
Mirasept
Nite white excel 2
Odosat D
Opalescence xtra
Oxigenal
Oxydol
Oxyfull
Oxysept
Oxysept I
Pegasyl
Perhydrol
Perone
Peroxaan
Peroxclean
Peroxide, hydrogen
Quasar brite
Select bleach
Superoxol
T-Stuff
Whiteness HP
Whitespeed
Xtra white
|
|
11 |
|
Polihexanide |
Approved, Investigational |
Phase 4 |
|
28757-47-3 |
|
Synonyms:
Polyhexamethylene biguanide
|
|
|
12 |
|
Ranibizumab |
Approved |
Phase 4 |
|
347396-82-1 |
459903 |
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
13 |
|
Verteporfin |
Approved, Investigational |
Phase 4 |
|
129497-78-5 |
|
Synonyms:
|
Vertéporfine
Verteporfinum
|
|
14 |
|
Propoxycaine |
Approved |
Phase 4 |
|
86-43-1 |
|
15 |
|
Laxatives |
|
Phase 4 |
|
|
|
16 |
|
Cathartics |
|
Phase 4 |
|
|
|
17 |
|
Echothiophate Iodide |
|
Phase 4 |
|
6736-03-4 |
10547 |
Synonyms:
(2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate
(2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate
2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide
2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide
2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide
2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide
217 MI
217-mi
2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid
2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]
2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide
2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide
513-10-0
AC1L1VFJ
AC1Q1TM0
Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide
Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate
C9H22NO3PS
CHEBI:59849
CHEMBL1200367
CID10547
D004456
D02193
DB01057
diethoxyphosphinylthiocholine iodide
Diethoxyphosphoryl-thiocholine iodide
Echodide
Echothiophate iodide
Echothiophate iodide (USP)
Ecostigmini jodidum
|
ECOTHIOPATE IODIDE
Ecothiopate iodide (JP15/INN)
Ecothiopati iodidum
Ecothiopati iodidum [INN-Latin]
Ecothiophate iodide
EINECS 208-152-1
Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide
Iodide, Echothiophate
Iodide, Ecothiopate
Iodide, Ecothiophate
Iodide, Phospholine
Iodure d'ecothiopate
Iodure d'ecothiopate [INN-French]
Ioduro de ecotiopato
Ioduro de ecotiopato [INN-Spanish]
LS-18625
MolPort-005-941-436
N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide
O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide
Phospholine
Phospholine (the pharmaceutical)
Phospholine iodide
Phospholine iodide (TN)
S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide
S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide
S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide
S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide
S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate
UNII-BA9QH3P00T
|
|
18 |
|
Carboxymethylcellulose Sodium |
|
Phase 4 |
|
|
|
19 |
|
Cholinesterase Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
21 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
22 |
|
Lubricant Eye Drops |
|
Phase 4 |
|
|
|
23 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
24 |
|
Ketorolac Tromethamine |
|
Phase 4 |
|
|
|
25 |
|
Analgesics |
|
Phase 4 |
|
|
|
26 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
27 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
28 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
29 |
|
Neuromuscular Blocking Agents |
|
Phase 4 |
|
|
|
30 |
|
Biguanides |
|
Phase 4 |
|
|
|
31 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
32 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
33 |
|
Photosensitizing Agents |
|
Phase 4 |
|
|
|
34 |
|
Angiogenesis Inhibitors |
|
Phase 4 |
|
|
|
35 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
36 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
37 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
38 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
39 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
40 |
|
Parasympatholytics |
|
Phase 4 |
|
|
|
41 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
42 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
43 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
44 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
45 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
46 |
|
Mydriatics |
|
Phase 4 |
|
|
|
47 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
48 |
|
Anesthetics |
|
Phase 4 |
|
|
|
49 |
|
Proxymetacaine |
|
Phase 4 |
|
|
|
50 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 853)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization |
Unknown status |
NCT01246089 |
Phase 4 |
ranibizumab injection |
2 |
A Prospective, Randomized, Multi Center Clinical Comparison Of Fellow Eyes Undergoing Lasik Using The Amo/Visx Customvue™ , The Bausch And Lomb Zyoptix And Planoscan And The Wavelight Allegretto Wave™ Wavefront Guided And Wavefront Optimized Excimer Laser Systems |
Unknown status |
NCT00770094 |
Phase 4 |
|
3 |
Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine |
Unknown status |
NCT00541177 |
Phase 4 |
atropine;tropicamide |
4 |
Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE |
Unknown status |
NCT03001401 |
Phase 4 |
|
5 |
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization |
Unknown status |
NCT02033018 |
Phase 4 |
Aflibercept Injection |
6 |
Echothiophate Iodide for the Prevention of Progression of Myopia |
Unknown status |
NCT02544529 |
Phase 4 |
Echothiophate Iodide 0.03% Ophthalmic Solution;Carboxymethylcellulose Sodium (0.5%) |
7 |
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK |
Unknown status |
NCT02071576 |
Phase 4 |
|
8 |
PHASE IV STUDY # 1162. Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism |
Unknown status |
NCT01628146 |
Phase 4 |
|
9 |
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK |
Unknown status |
NCT01977807 |
Phase 4 |
|
10 |
A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia |
Unknown status |
NCT02112968 |
Phase 4 |
|
11 |
Randomized, Single Blinded Controlled Trial for Evaluation of the Safety and Efficacy of Loteprednol Versus Fluorometholone After Photorefractive Keratectomy for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study |
Unknown status |
NCT02974387 |
Phase 4 |
Fluorometholone(FML);Loteprednol (Lotemax) |
12 |
A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik |
Completed |
NCT01387360 |
Phase 4 |
|
13 |
Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study) |
Completed |
NCT00937105 |
Phase 4 |
|
14 |
A Prospective, Randomised Trial of Photo-Refractive Keratectomy (PRK) and Laser-in-Situ-Keratomileusis (LASIK) for Correction of Myopia |
Completed |
NCT00404105 |
Phase 4 |
|
15 |
The Influence of Atropine on Choroidal Thickness |
Completed |
NCT03158142 |
Phase 4 |
Atropine Sulfate 1% Oph Soln |
16 |
A Prospective Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients |
Completed |
NCT01173198 |
Phase 4 |
|
17 |
Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser |
Completed |
NCT01746589 |
Phase 4 |
|
18 |
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization |
Completed |
NCT00797992 |
Phase 4 |
Injection |
19 |
Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study |
Completed |
NCT03042871 |
Phase 4 |
0.5mg intravitreal ranibizumab |
20 |
Effect of Orthokeratology on Myopia Progression in Chinese Children |
Completed |
NCT02186184 |
Phase 4 |
|
21 |
A Three Arm Prospective Clinical Evaluation of Three FDA-approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction |
Completed |
NCT01225952 |
Phase 4 |
|
22 |
Clinical Evaluation of the One-Piece Tecnis Multifocal IOL, Model ZMB00 |
Completed |
NCT01210807 |
Phase 4 |
|
23 |
A Three Arm Prospective Clinical Evaluation of Three FDA Approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction. |
Completed |
NCT01122576 |
Phase 4 |
|
24 |
Visual Performance After Implantation of an Aspheric Multifocal Diffractive Intraocular Lens |
Completed |
NCT01065064 |
Phase 4 |
|
25 |
Randomised Clinical Investigation of the Bi Flex M Multifocal Intraocular Lens |
Completed |
NCT02338882 |
Phase 4 |
|
26 |
Effects of Contact Lens Care Regimens on the Corneal Epithelium |
Completed |
NCT00349882 |
Phase 4 |
Marketed multipurpose disinfection regimen |
27 |
Evaluation of Stenfilcon A Versus Etafilcon A |
Completed |
NCT01809834 |
Phase 4 |
|
28 |
Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds |
Completed |
NCT00564213 |
Phase 4 |
PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds |
29 |
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap |
Completed |
NCT01693939 |
Phase 4 |
|
30 |
Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort With Daily Wear FDA Group IV Hydrogel Lenses |
Completed |
NCT00349843 |
Phase 4 |
Marketed soft lens multipurpose disinfection regimen |
31 |
Clinical Comfort Evaluation of Biofinity and Acuvue Oasys Lenses |
Completed |
NCT01695369 |
Phase 4 |
|
32 |
Product Performance of Bausch & Lomb PureVision® Contact Lens When Compared to Johnson & Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily. |
Completed |
NCT00640341 |
Phase 4 |
|
33 |
Clinical Study of Approved Contact Lenses |
Completed |
NCT03351101 |
Phase 4 |
|
34 |
Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK |
Completed |
NCT00889941 |
Phase 4 |
|
35 |
Efficacy and Safety of Low Dose Atracurium Added to Lidocaine, Bupivacaine and Hyaluronidase Mixture in Percaruncular Peribulbar Anesthesia for High Myopes Undergoing Phacoemulsification: A Randomized Controlled Trial. |
Completed |
NCT03243500 |
Phase 4 |
Atracurium;Lidocaine 2%;Bupivacaine 0.5%;hyaluronidase powder |
36 |
Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist |
Completed |
NCT02024698 |
Phase 4 |
|
37 |
BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study |
Completed |
NCT02537730 |
Phase 4 |
|
38 |
Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision |
Completed |
NCT00627302 |
Phase 4 |
PEG-400;Systane |
39 |
Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses |
Completed |
NCT01707238 |
Phase 4 |
|
40 |
Daily Disposable Comparison Study |
Completed |
NCT02094677 |
Phase 4 |
|
41 |
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia |
Completed |
NCT03409250 |
Phase 4 |
Ranibizumab, Lucentis |
42 |
Long-term Effects of Laser Refractive Surgery |
Completed |
NCT00350246 |
Phase 4 |
|
43 |
Clinical Performance of Stenfilcon A Versus Filcon II 3 |
Completed |
NCT01808209 |
Phase 4 |
|
44 |
A Prospective, Multi Center Clinical Comparison of Fellow Eyes Undergoing Lasik Using the Wavelight Allegretto Wave™ Excimer Laser in One Eye and the Amo/Visx Customvue™ or the Ladarvision 4000 Excimer Laser System in the Contralateral Eye |
Completed |
NCT00821236 |
Phase 4 |
|
45 |
Contralateral Eye Comparison of Visual Outcomes and Patient Satisfaction After Routine Phacoemulsification and Implantation of ReSTOR and ReZoom IOLs |
Completed |
NCT00366587 |
Phase 4 |
|
46 |
The Effects of Low Dose Atropine on Choroidal Thickness |
Completed |
NCT03544827 |
Phase 4 |
Atropine;Atropine |
47 |
Single-Center Clinical Evaluation of Daily Disposable Contact Lenses |
Completed |
NCT02097030 |
Phase 4 |
|
48 |
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). |
Completed |
NCT00620893 |
Phase 4 |
PEG- 400 based artificial tear;Systane |
49 |
Corneal and Conjunctival Sensitivity and Staining Study |
Completed |
NCT00455455 |
Phase 4 |
Optifree RepleniSH Multipurpose Disinfecting Solution;ReNu Multiplus Multipurpose Solution |
50 |
Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study |
Completed |
NCT01250925 |
Phase 4 |
ReNu MultiPlus® MultiPurpose Solution;OPTI-FREE® RepleniSH®;Clear Care® |
|